This is a study to determine the safety and tolerability of pantoprazole (Protonix) in infants between the ages 1 month through 11 months with presumed gastroesophageal reflux disorder. This national study is currently recruiting patients.
Read moreInsurance company authorization of medications can be challenging for both patients and physicians. Proton pump inhibitors, because of... Read more »
Yes, acid-reducing medications can cause bone loss. Many medications and medical disorders can cause bone loss; but in this article... Read more »
This is a study to determine the minimal clinical difference in gastroesophageal reflux disorder (GERD) patients using pantoprazole (Protonix) versus... Read more »
Wyeth Pharmaceuticals will be conducting a clinical trial to evaluate the use of pantoprazole (Protonix) in children ages 1 to 5. This national study... Read more »
Drugmakers Atlana and Wyeth have sued Schwarz Pharma to stop the rival company from making a generic form of Protonix (pantoprazole). Schwarz Pharma... Read more »
Drugmaker Teva has received tentative approval for a generic form of Protonix delayed-release tablets (pantoprazole sodium). Final approval is... Read more »
Drugmaker Wyeth has launched a generic version of their acid-reflux medication Protonix. The launch comes in response to the generic version of... Read more »